146 related articles for article (PubMed ID: 28347660)
1. Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P450 2D6.
Niwa T; Shizuku M; Yamano K
Arch Biochem Biophys; 2017 Apr; 620():23-27. PubMed ID: 28347660
[TBL] [Abstract][Full Text] [Related]
2. Effect of Cytochrome P450 (CYP) 2D6 Genetic Polymorphism on the Inhibitory Action of Antidepressants on CYP2D6-Mediated Dopamine Formation from p-Tyramine.
Niwa T; Yanai M; Matsumoto M; Shizuku M
J Pharm Pharm Sci; 2018; 21(1):135-142. PubMed ID: 29602316
[TBL] [Abstract][Full Text] [Related]
3. [Metabolic Activities Catalyzed by Human Cytochrome P450 (CYP) 2D6 and CYP3A Subfamily Members and Effect of Various Compounds, Including Endogenous Steroid Hormones, on These Activities].
Niwa T
Yakugaku Zasshi; 2024; 144(2):197-202. PubMed ID: 38296497
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory and Stimulatory Effects of Selective Serotonin Reuptake Inhibitors on Cytochrome P450 2D6-mediated Dopamine Formation from p-Tyramine.
Niwa T; Sugimoto S
J Pharm Pharm Sci; 2019; 22(1):585-592. PubMed ID: 31804922
[TBL] [Abstract][Full Text] [Related]
5. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.
Niwa T; Hiroi T; Tsuzuki D; Yamamoto S; Narimatsu S; Fukuda T; Azuma J; Funae Y
Brain Res Mol Brain Res; 2004 Oct; 129(1-2):117-23. PubMed ID: 15469888
[TBL] [Abstract][Full Text] [Related]
6. Role of amino acids at positions 34, 296, and 486 of cytochrome P450 2D6 in the stimulatory and inhibitory effects of psychotropic agents on dopamine formation from
Niwa T; Arima J; Michihiro Y
Xenobiotica; 2021 Nov; 51(11):1229-1235. PubMed ID: 34605737
[TBL] [Abstract][Full Text] [Related]
7. Stimulatory and inhibitory effect of antipsychotic agents including dopaminergic neuro-depressants on dopamine formation from p-tyramine mediated by cytochrome P450 2D6.
Niwa T; Yamamoto Y
Drug Metab Bioanal Lett; 2023 Sep; ():. PubMed ID: 37711131
[TBL] [Abstract][Full Text] [Related]
8. Dopamine formation from tyramine by CYP2D6.
Hiroi T; Imaoka S; Funae Y
Biochem Biophys Res Commun; 1998 Aug; 249(3):838-43. PubMed ID: 9731223
[TBL] [Abstract][Full Text] [Related]
9. Effect of Human Cytochrome P450 2D6 Polymorphism on Progesterone Hydroxylation.
Niwa T; Sasaki S; Yamamoto Y; Tanaka M
Eur J Drug Metab Pharmacokinet; 2022 Sep; 47(5):741-747. PubMed ID: 35838883
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues.
Hutzler JM; Walker GS; Wienkers LC
Chem Res Toxicol; 2003 Apr; 16(4):450-9. PubMed ID: 12703961
[TBL] [Abstract][Full Text] [Related]
11. Contribution of the human cytochrome P450 2C subfamily to the metabolism of and the interactions with endogenous compounds including steroid hormones.
Niwa T; Yasuda S; Yamamoto Y; Murakami M; Ishii R
Pharmazie; 2021 Dec; 76(12):611-613. PubMed ID: 34986958
[TBL] [Abstract][Full Text] [Related]
12. The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: An in vitro study.
Bromek E; Haduch A; Daniel WA
Eur J Pharmacol; 2010 Jan; 626(2-3):171-8. PubMed ID: 19818757
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
14. Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Naunyn Schmiedebergs Arch Pharmacol; 2019 Aug; 392(8):1015-1029. PubMed ID: 31025144
[TBL] [Abstract][Full Text] [Related]
15. Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis.
Guengerich FP; Hanna IH; Martin MV; Gillam EM
Biochemistry; 2003 Feb; 42(5):1245-53. PubMed ID: 12564927
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 2D6 polymorphism and character traits.
Suzuki E; Kitao Y; Ono Y; Iijima Y; Inada T
Psychiatr Genet; 2003 Jun; 13(2):111-3. PubMed ID: 12782969
[TBL] [Abstract][Full Text] [Related]
17. Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain.
Niwa T; Okada K; Hiroi T; Imaoka S; Narimatsu S; Funae Y
Biol Pharm Bull; 2008 Mar; 31(3):348-51. PubMed ID: 18310890
[TBL] [Abstract][Full Text] [Related]
18. Mechanism-based inactivation of cytochrome P450 2D6 by chelidonine.
Liu Y; Cui T; Peng Y; Ji M; Zheng J
J Biochem Mol Toxicol; 2019 Feb; 33(2):e22251. PubMed ID: 30368994
[TBL] [Abstract][Full Text] [Related]
19. Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding.
Wang A; Stout CD; Zhang Q; Johnson EF
J Biol Chem; 2015 Feb; 290(8):5092-5104. PubMed ID: 25555909
[TBL] [Abstract][Full Text] [Related]
20. Human liver enzymes responsible for metabolic elimination of tyramine; a vasopressor agent from daily food.
Niwa T; Murayama N; Umeyama H; Shimizu M; Yamazaki H
Drug Metab Lett; 2011 Aug; 5(3):216-9. PubMed ID: 21679153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
